Last reviewed · How we verify
Daflon
At a glance
| Generic name | Daflon |
|---|---|
| Also known as | Diosmin, Venoruton, Antistax |
| Sponsor | Vidfarma Indústria de Medicamentos Ltda. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of TriThien Duoc Capsules in Grade II Internal Haemorrhoids Patients With Bleeding Compared to Diosmin. (PHASE3)
- Clinical Trial of Aesculus Hippocastanum and Associations Versus Diosmina and Hesperidina in Chronic Venous Insuficiency (PHASE4)
- Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (NA)
- Silymarin vs Hesperidin/Diosmin in Fibromyalgia (NA)
- Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis (NA)
- Effects of a Dietary Supplement Composed of Diosmin, Hesperidin, Bromelain, and Ruscus Aculeatus on the Quality of Life in Subjects With Lower Limb Disorders Possibly Prodromal to Chronic Venous Disease (NA)
- Glue Embolization vs Conservative Treatment for Pelvic Congestion Syndrome (NA)
- Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daflon CI brief — competitive landscape report
- Daflon updates RSS · CI watch RSS
- Vidfarma Indústria de Medicamentos Ltda. portfolio CI